RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/15087111http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/15087111http://www.w3.org/2000/01/rdf-schema#comment"Limb-girdle muscular dystrophy type 2C is an autosomal-recessive disorder caused by mutations in gamma-sarcoglycan encoding gene. This disease is characterized by childhood onset of progressive muscular dystrophy. Because of the clinical presentation, this disorder may be misdiagnosed as a dystrophinopathy. Two males (Patients A and B) from one Turkish family and one male (Patient C) from a Moroccan family had progressive walking disturbances for several years, exercise intolerance, and leg pains. Clinical examination revealed limb-girdle weakness and calf hypertrophy. Serum creatine kinase levels ranged from 1100 to 19000 U/L. The initial findings and course of the disease were less severe in Patient B compared with his brother (Patient A) at the same age. By means of immunohistochemistry on muscle biopsy all patients manifested reduced expression of alpha-, beta-, gamma-, and delta-sarcoglycans. DNA sequence analysis revealed a homozygous splice site mutation in exon 5 (IVS5+2T>C) in the Turkish family. In the patient from the Moroccan family a homozygous nonsense mutation in exon 2 (93G>A;Trp31X) was present. In conclusion, this report describes the clinical, histologic, and immunohistochemical characteristics of three children with limb-girdle muscular dystrophy type 2C. Two novel mutations in the gamma-sarcoglycan gene were present. We found phenotypic differences in two brothers."xsd:string
http://purl.uniprot.org/citations/15087111http://purl.org/dc/terms/identifier"doi:10.1016/j.pediatrneurol.2003.11.006"xsd:string
http://purl.uniprot.org/citations/15087111http://purl.uniprot.org/core/author"Vermeer S."xsd:string
http://purl.uniprot.org/citations/15087111http://purl.uniprot.org/core/author"Willemsen M.A."xsd:string
http://purl.uniprot.org/citations/15087111http://purl.uniprot.org/core/author"Verrips A."xsd:string
http://purl.uniprot.org/citations/15087111http://purl.uniprot.org/core/author"Hamel B.C."xsd:string
http://purl.uniprot.org/citations/15087111http://purl.uniprot.org/core/author"Ginjaar I.B."xsd:string
http://purl.uniprot.org/citations/15087111http://purl.uniprot.org/core/author"ter Laak H.J."xsd:string
http://purl.uniprot.org/citations/15087111http://purl.uniprot.org/core/date"2004"xsd:gYear
http://purl.uniprot.org/citations/15087111http://purl.uniprot.org/core/name"Pediatr Neurol"xsd:string
http://purl.uniprot.org/citations/15087111http://purl.uniprot.org/core/pages"291-294"xsd:string
http://purl.uniprot.org/citations/15087111http://purl.uniprot.org/core/title"Novel mutations in three patients with LGMD2C with phenotypic differences."xsd:string
http://purl.uniprot.org/citations/15087111http://purl.uniprot.org/core/volume"30"xsd:string
http://purl.uniprot.org/citations/15087111http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/15087111
http://purl.uniprot.org/citations/15087111http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/15087111
http://purl.uniprot.org/uniprot/#_B2RE70-mappedCitation-15087111http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/15087111
http://purl.uniprot.org/uniprot/#_A8K3K5-mappedCitation-15087111http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/15087111
http://purl.uniprot.org/uniprot/#_Q13326-mappedCitation-15087111http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/15087111
http://purl.uniprot.org/uniprot/A8K3K5http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/15087111
http://purl.uniprot.org/uniprot/B2RE70http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/15087111
http://purl.uniprot.org/uniprot/Q13326http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/15087111